Charles River Laboratories International, Inc.
Market Cap
$7.57B
P/E Ratio
-53.00
EPS
$-2.90
Dividend Yield
0.00%
52-Week Range
$91.86 — $228.88
Volume
542.53K
Avg Volume
934.73K
Beta
1.65
P/E (TTM)
-53.00
Forward P/E
13.99
PEG Ratio
0.66
P/S (TTM)
2.14
P/B (TTM)
2.71
P/FCF
41.02
EV/EBITDA
49.22x
EV/Sales
—
ROE (TTM)
-0.04%
ROA (TTM)
-0.02%
ROIC
0.02%
Gross Margin
0.33%
Operating Margin
0.11%
Net Margin
0.05%
Debt/Equity
0.97
Current Ratio
1.29
EPS Growth (YoY)
-0.17%
Revenue Growth (YoY)
+0.04%
EPS Growth (3Y)
-0.26%
EPS Growth (5Y)
-0.06%
Sales Growth (3Y)
+0.05%
Sales Growth (5Y)
+0.09%
EPS Est (This Year)
$10.98
EPS Est (Next Year)
$12.02
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$4.34
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $201.14(30.9% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
49.22M
Float
48.66M
Free Float %
98.88%
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
NYSE
IPO Date
2000-06-23
Employees
18700
CEO
James C. Foster
Index Membership
S&P 500
Website
https://www.criver.com
Charles River Laboratories International, Inc. (CRL) is a healthcare company in the medical - diagnostics & research industry listed on the NYSE. With a market capitalization of $7.57B, a P/E ratio of -53.00, CRL is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare CRL against other stocks using dozens of fundamental and technical filters.
Charles River Laboratories International, Inc. (CRL) has a trailing twelve-month (TTM) P/E ratio of -53.00. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Charles River Laboratories International, Inc. (CRL) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Charles River Laboratories International, Inc. (CRL) has a market capitalization of $7.57 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Charles River Laboratories International, Inc. (CRL) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $201.14 implies 30.9% upside from the current price.